We evaluated an amphotericin treatment strategy on the basis of duration of candidemia and clinical findings. Patients without neutropenia who had uncomplicated candidemia received 200 mg of amphotericin B over 5-7 days if they had had р1 day of documented positive blood cultures (SC group) or a total of 500 mg of amphotericin B over 14-20 days if they had had 11 day of positive cultures (PC group). The clinical cure rate was 93% (95% confidence interval [CI], 77%-99%; episodes) in the SC group, with no relapses (median follown = 29 up, 272 days). The clinical cure rate was 83% (95% CI, 64%-94%; episodes) in the PC n = 29 group, with 1 relapse (4.2%). The results of this pilot study suggest that patients with candidemia may be stratified into risk groups on the basis of the duration of positive blood cultures and other clinical findings. Decisions about the duration of therapy can be made 4-7 days after initiation of treatment. Carefully selected patients with transient uncomplicated candidemia may be safely treated with a short course of amphotericin B. Further prospective validation of this concept should be undertaken particularly to evaluate the impact on lowfrequency late complications (e.g., endophthalmitis).
Candidemia has become an important clinical problem because of its increasing frequency and its occurrence among immunosuppressed patients [1] [2] [3] [4] [5] . Studies of the treatment of candidemia have been complicated by differences in the natural history of this disease [6] [7] [8] [9] [10] [11] [12] [13] . Despite its frequency and importance, there continues to be substantial debate over which antifungal agent or combination to use, appropriate dosage, and the optimal duration of therapy [13] . In a prior study of candidemia at this institution, a group of patients with transient candidemia had good outcomes despite receiving no antifungal therapy [14] . Patients in this group had no underlying disease, had !1 day of documented candidemia, and had central intravenous catheters removed. In contrast, patients with documented sustained candidemia (12 days' duration) had a mortality rate of 74%. Therefore, on the basis of these findings we developed a strategy for the treatment of candidemia that was based on differentiating patients with positive blood cultures documented for !1 day from those with sustained positive blood cultures. The former group received a short-course regimen of amphotericin B (SC group), because of an earlier report of success with this regimen [15] . The latter group was treated with a more prolonged course of amphotericin B (PC group). Patients with evidence of deep-seated disease (e.g., abscess, retinitis, endocarditis) were treated individually and were not the subject of this study. The primary goal of this study was to prospectively evaluate the safety and efficacy of this treatment strategy for candidemia.
Methods
Study population. All adult patients hospitalized at Barnes and Jewish Hospitals with a blood culture positive for Candida were eligible for enrollment. Potential participants were identified prospectively by screening, each weekday, the microbiology log books for blood cultures positive for Candida isolates. All patients who were still hospitalized at the time of culture positivity were screened for inclusion in the study. The patient's primary physician was informed of the study protocol before enrollment. The study was approved by the Washington University Human Studies Committee.
Participants had to agree to be under the care of 1 of the faculty members of the Division of Infectious Diseases. Participants were excluded from the protocol for the following reasons: age !18 years; receipt of 172 h of amphotericin B treatment or a total dose of 2 mg/kg amphotericin B before diagnosis of candidemia; receipt of mg/dL and not undergoing maintenance dialysis); culture positive for Candida lusitaniae, because of its inherent resistance to amphotericin B; evidence of fungal endocarditis or meningitis; receipt of a bone marrow transplant; neutropenia, defined as an absolute neutrophil count !500 cells/mm 3 ; or receipt of chemotherapy for acute leukemia. Enrollment began 1 August 1993 and ended 1 March 1995.
Intervention. Patients were assigned to a treatment strategy on the basis of documented duration of candidemia and specific clinical findings. All patients with a blood culture positive for yeast were evaluated. Typically, blood cultures yielded yeast within 24-48 h after blood was drawn. Blood was drawn for follow-up blood cultures on the day that growth was detected from the original culture. Amphotericin B was then begun for all patients after the follow-up blood sample was drawn. Normotensive patients who had a blood culture positive for Candida documented for р1 day were treated with a short course of intravenous amphotericin B (200 mg total over 5-7 days; SC group). In addition, all indwelling central venous catheters present at the time of the candidemia had to be removed. Patients who had indwelling central venous catheters that would not be removed or who were hypotensive (defined as systolic blood pressure !90 mm Hg) were treated in the PC group. Because central catheters may be colonized or infected with Candida, we did not feel comfortable using !500 mg of amphotericin B to treat patients whose catheter would remain in place, even if they had р1 day of documented positive blood cultures. Patients with 11 day of documented positive blood cultures without evidence of invasive disease (defined as the presence of an endovascular focus of infection, a deep-seated abscess, urinary tract infection, or retinal findings) or those with р1 day of documented positive blood cultures who were hypotensive were treated with a more prolonged course of intravenous amphotericin B (500 mg total over 14-20 days; PC group). All other patients with candidemia who did not meet the eligibility requirements for the SC or PC groups were designated as having complicated candidemia. Treatment for these patients was left to the discretion of their physician and is not the subject of this report.
All patients received a 1-mg test dose of amphotericin B on the first day that their candidemia was detected. If the test dose was tolerated, participants received 0.25 mg/kg amphotericin B that same day. On the second day of therapy and every day thereafter until the treatment course was complete, participants received 0.5 mg/kg/day amphotericin B. Assignment to the SC or PC group was made 4-7 days into the treatment of candidemia by 1 of the protocol team members on the basis of the duration of candidemia and clinical findings (e.g., hypotension, presence of central venous catheters, deep-seated disease). Dose modifications of amphotericin B therapy for adverse reactions (e.g., elevated serum creatinine level) were done at the discretion of the treating physician, with the intent to administer the predetermined amount of amphotericin B (either 200 or 500 mg). All patients were pretreated with oral diphenhydramine, 50 mg, and acetaminophen, 500 mg, 30 minutes prior to the amphotericin B infusion.
Study evaluations. Patients were evaluated daily while they were receiving amphotericin B by 1 of the study investigators (M.G. or J.D.) until they were discharged from the hospital. Direct fundoscopy was performed at the bedside at the time of diagnosis. Blood cultures were done on the day the patient's original culture became positive for Candida. Subsequently, at least 1 blood sample was collected and cultured each day until cultures yielded sterile results after 72 h of incubation. Patients without follow-up blood cultures were excluded from this study. Serum creatinine, potassium, and magnesium levels were monitored at least twice weekly while the patient was being treated with amphotericin B. Evaluations for recurrence of disease and survival were done at 1, 3, 6, and 12 months. All participants were followed until death or for a minimum of 6 months.
Study definitions. Clinical cure required all of the following: completion of the predetermined course of amphotericin B therapy; presence of blood cultures negative for Candida while receiving treatment; and remission of all signs and symptoms attributable to candidemia. Survival was followed for all participants for a minimum of 6 months. Mortality was attributed, in part, to candidemia if the patient died within 1 week of having positive blood cultures. A relapse was defined as the recurrence of a positive blood culture with the same species of Candida that had been identified in the prior treated episode from a patient who had been clinically cured. The duration of follow-up is reported as the amount of time after completion of the assigned course of amphotericin B.
Statistics. Statistical analyses were done by use of SAS-PC, version 6.11 (SAS institute, Cary, NC). Categorical data were analyzed with a x 2 test. Continuous data were analyzed by use of the Wilcoxon rank sum test for non-normally distributed data. The CIs for the PC group were calculated by use of exact methods and those for the SC group were calculated with the binomial method for no successes as described by Louis Thomas [16] . P р .05 was considered to be significant.
Results
Ineligible patients. There were 175 patients with blood cultures positive for Candida species during the 18-month study period. One hundred and six (61%) did not meet eligibility criteria for enrollment for the following reasons: evidence of invasive disease at the time of diagnosis (34); death prior to initiation of any antifungal therapy (23); baseline creatinine level 12.5 mg/dL and not undergoing maintenance dialysis (16); excluding condition (e.g., bone marrow transplant, acute leukemia or neutropenia; 9); patient not hospitalized (either discharged or had never been admitted) at the time culture became positive (7); patient not receiving care by the protocol team service (6); prior therapy, either for 172 h or with 2 mg/kg amphotericin B or for 172 h with fluconazole (5); failure to ask patient to participate in the study (3); culture positive for Candida lusitaniae (1); age of !18 years (1); and leaving against medical advice during treatment (1) .
Study population. There were 38 patients eligible for the SC group and 31 eligible for the PC group. Eight patients eligible for the SC group were not included in analysis of outcome for the following reasons: the treating physician elected to withhold antifungal therapy (6); the treating physician wanted to use more amphotericin B than allowed by the protocol (1); and a serious adverse reaction (hypotension and shortness of Baseline characteristics. The baseline characteristics of the study population are shown in table 1. There were no significant differences between the SC and PC groups in the severity of illness (APACHE [acute physiology and chronic health evaluation] II scores) or age at baseline. The groups had a similar spectrum of underlying conditions previously associated with the occurrence of candidemia (table 1). Parenteral nutrition was more common in the SC group (66% vs. 24%; , x 2 test), P = .002 whereas recent surgery was more common in the PC group (55% vs. 24%; , x 2 test). The etiologic agents of the P = .02 episodes of candidemia are shown in table 2. The median duration of documented candidemia in the PC group was 2 days (range, 1-10 days). Six persons assigned to the PC group had р1 day of documented candidemia. Five were assigned to the PC group because of hypotension at the time of the development of candidemia and 1 because of the presence of an indwelling intravenous catheter that was not removed during treatment of the episode of candidemia.
Clinical outcome and survival. The outcomes for patients with candidemia are shown in table 3. Ninety-three percent (27 of 29) of the candidemia episodes in the SC group were cured. Two patients in the SC group died within 1 week of being diagnosed with candidemia. One patient was a 92-year-old woman admitted with severe aspiration pneumonia who developed candidemia 5 days before her death. She had received 3 days of amphotericin B treatment and had 4 follow-up blood cultures negative for Candida when her family requested no further aggressive medical interventions. The second patient was an 82-year-old woman with pancreatic cancer who underwent endoscopic retrograde cholangiopancreatography complicated by cholangitis. She was diagnosed with candidemia 8 days before her death. She had received 3 days of amphotericin B treatment and had 4 negative blood culture results of samples taken on different days. She developed acute gastrointestinal bleeding with hypotension and died.
Eighty-three percent (24 of 29) of the candidemia episodes in the PC group were cured. One patient in the PC group died within 1 week of being diagnosed with candidemia. She was a 64-year-old woman with multiple medical problems who underwent urgent coronary artery bypass grafting. Her postoperative course was complicated by a hypoxic-ischemic encephalopathy and ventilator dependence. She had an asystolic arrest on the day she developed candidemia. Two days later, amphotericin B treatment was begun (when the culture results became known). Her family decided not continue aggressive medical interventions and she died. The remaining patients who died in the PC group before completing their treatment for candidemia all had significant underlying illnesses that were more likely than the candidemia to have contributed to their death. None of these deaths occurred within 7 days of the diagnosis of candidemia. All exhibited a response to amphotericin B (afebrile with follow-up blood cultures negative for Candida) before their deaths. The 30-day mortality was lower in the SC group than in the PC group (10% vs. 25%; , x 2 test); however, this was not P = .15 statistically significant. Overall, survival for 130 days was associated with lower baseline APACHE II scores (median score, 13 vs. 19;
, Wilcoxon rank sum test) and younger age P ! .001 (median age, 59 years vs. 70 years;
, Wilcoxon rank P ! .001 sum test).
Relapse. Twenty-seven patients (93%) completed shortcourse therapy and were followed for a minimum of 6 months or until they died. There were no relapses (95% CI, 0-10.5%; binomial confidence interval for no successes) in the SC group after completion of treatment, with a median length of followup of 272 days (range, 13-542 days). Twenty-four patients (86%) completed prolonged-course therapy and were followed for a minimum of 6 months or until they died. One relapse occurred (4.2%; 95% CI, 0.11%-21.1%) after completion of the assigned treatment course, with a median length of follow-up of 197.5 days (range, 1-468 days). This patient was a 64-yearold woman with ovarian cancer who underwent surgical removal of the tumor complicated by persistent (10 days) candidemia with Candida albicans. Despite prolonged candidemia, there was no evidence of deep-seated disease at the time of her assignment to receive 500 mg of amphotericin B. She completed her amphotericin therapy at home and was readmitted with recurrent fever 1 day after finishing 510 mg of amphotericin B. She was diagnosed with acute cholecystitis. Culture of purulent material from the cholecystostomy tube yielded C. albicans. She received an additional 480 mg of amphotericin B without subsequent relapse.
Complications of therapy. One patient in the SC group had to discontinue amphotericin B prematurely because of an adverse event. This patient developed hypertension, chest pain, and congestive heart failure after receiving the 1-mg test dose, and treatment was changed to fluconazole. The relationship of amphotericin B to the clinical adverse event was not clear. Complications of amphotericin B therapy were more common in the PC group than in the SC group (68% vs. 38%; , x 2 P = .02 test). Hypomagnesemia (!2.0 mg/dL) was more common in the PC group (55% vs. 7%; , x 2 test). There was no signif-P ! .001 icant difference in the incidence of hypokalemia (!3.0 mg/dL) between the groups (38% vs. 28%; , x 2 test). There was P = 0.4 a nonsignificant trend toward a higher incidence of elevated creatinine levels (150% rise from baseline) during treatment with amphotericin B in the PC group than in the SC group (34% vs. 17%; , x 2 test). The creatinine value did not P = 0.1 return to baseline in 1 patient from each group. No patient required dialysis as a result of amphotericin B therapy. There were no differences in the incidence of febrile reactions, nausea, or vomiting between the treatment groups (data not shown).
Discussion
We have demonstrated that patients can be stratified into different risk groups on the basis of the documented duration of candidemia and associated clinical findings. It is important to note that the majority (59%) of patients with candidemia at our institution presented with complicated disease. The 30-day mortality rate for patients with complicated disease was 50%. Thus the patients we selected represent the least ill of all patients with candidemia at our institution. In these patients with relatively uncomplicated candidemia, short-course amphotericin B treatment appeared to be effective. Persons with р1 day of documented uncomplicated candidemia were safely treated with 200 mg of amphotericin B over 5-7 days. This conclusion must be tempered by the fact that this study was not designed to prove that the rate of relapse of disease due to Candida would be equivalent in patients treated with shorter versus longer, more standard courses of antifungal therapy.
The notion of shorter courses of amphotericin B treatment for candida infections is not new [15] . Three persons with candidemia (including 2 with evidence of disseminated disease) were successfully treated with 80-355 mg of amphotericin B over 10-18 days [15] . More recently, Donowitz and Hendley [8] reported their experience using short-course amphotericin B to treat 30 children. They concluded that once the bloodstream is sterile, amphotericin B at 0.5 mg/kg/day can be given for 7-14 days. Nguyen et al. [9] reported no difference in mortality in a study of lower versus higher doses of amphotericin B (р500 mg vs. 1500 mg). The overall cure rate was ∼60% in each group. These studies suggest that lower doses and shorter durations of amphotericin B therapy in certain groups of patients may be as effective as standard treatment courses (e.g., 1 g over 14-21 days).
The concept that patients with candidemia can be stratified into different groups by duration of candidemia and associated clinical findings is useful in predicting outcome. Our study identified 2 groups that have relatively good outcomes when treated with courses of amphotericin B that are shorter than what is often recommended. This risk stratification approach to management of candidemia is supported by the difference in mortality rates observed in patients who were not eligible for either of our study treatment arms. The 30-day mortality rate for patients with complicated candidemia (invasive disease and/or a significant underlying condition) who were not eligible for our study was 50%, versus 19% in our 2 study groups combined ( , x 2 test). Furthermore, the mortality rate in our study P ! .01 patients was lower than the crude mortality rate of 57% re-ported by Wey et al. [17] . Therefore, our approach is useful in identifying patients with lower or higher mortality rates associated with candidemia.
On the basis of our studies, we believe that optimal management of patients with candidemia is determined by stratifying patients according to the severity of their infection within the first week. From a practical standpoint, stratification into complicated or uncomplicated groups is not possible on the day blood cultures become positive. Clinicians typically request further studies to evaluate the extent of disease due to Candida (e.g., blood cultures, eye examinations, renal ultrasound) before deciding on the type, dose, and duration of antifungal therapy. Nevertheless, clinicians are often forced to initiate antifungal therapy on the day that cultures become positive. Fluconazole is now considered the primary treatment of choice for uncomplicated candidemia [13] . This recommendation was based on several recent comparative studies of amphotericin B and fluconazole [3-7, 10, 18] . In each of these trials, efficacy was similar, and the incidence of dose-limiting toxicities was significantly lower in persons treated with fluconazole. Therefore, fluconazole has supplanted amphotericin B as the primary treatment of choice for uncomplicated candidemia. Although we agree that fluconazole is safe and effective for uncomplicated candidemia, the empirical initiation of amphotericin B may be more appropriate for the majority of patients who present with nosocomial candidemia. Most experts agree that amphotericin B should be used for patients with severe or complicated candidemia [13] . Therefore, our management strategy allows therapy to be tailored to the needs of the individual patient with candidemia on the basis of clinical and laboratory information between the fourth and seventh day of therapy.
There are some important limitations in this study. This was not a randomized comparison of shorter-versus longer-duration amphotericin B. The sample size of such a trial would require a minimum of 300 patients in each arm to detect a significant difference in mortality (e.g., 10% vs. 5%). In addition, we recognize that some clinicians would feel uncomfortable with a relapse rate of 10% for uncomplicated candidemia (this is the upper bound of the 95% CI for our estimate of the relapse rate in the SC group). To definitely prove that the true relapse rate is !5% would require 1200 patients with transient uncomplicated candidemia, assuming that the observed relapse rate was 2%. Our data do not permit us to draw any conclusions about low-frequency late complications such as endophthalmitis or osteomyelitis. Last, we recognize that fluconazole is clearly useful for the treatment of candidemia. Our study was not designed to determine whether initiation of amphotericin B or fluconazole is the optimal treatment strategy for patients who present with candidemia. However, we believe that the strategic approach outlined in this study is applicable to any antifungal agent.
In conclusion, we have developed a clinically useful strategic approach to the management of candidemia. The documented duration of candidemia has important prognostic and management implications. Carefully selected patients without neutropenia who have uncomplicated transient candidemia (р1 day) can be safely and effectively treated with a short course of amphotericin B (total dose, 200 mg over 5-7 days). Adverse events are uncommon and rarely lead to interruption in therapy or significant sequelae. Nonneutropenic patients without complicated disease who have documented candidemia for 11 day can be successfully treated with a more prolonged course of amphotericin B (total dose, 500 mg over 14-20 days). Future comparative trials of antifungal therapy should stratify patients by the duration of documented candidemia. The concepts tested in this pilot study should be validated with a larger, prospective trial.
